Soonchunhyang Med Sci.  2014 Dec;20(2):168-171. 10.0000/sms.2014.20.2.168.

A Case of Hepatitis B Virus Reactivation in a HBsAg-Negative and Anti-HBs-Positive Patient with Diffuse Large B-Cell Lymphoma after Rituximab plus CHOP Chemotherapy

Affiliations
  • 1Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea. ckp@hallym.or.kr

Abstract

The reactivation of hepatitis B virus (HBV) is well known complication among lymphoma patient related with chemotherapy. Rituximab is monoclonal antibody that targets B-lymphocytes for treatment of lymphoma and it increases reactivation of HBV. Although most of reactivation occurs in HBV carrier, it can also rarely occur when hepatitis B surface antigen (HBsAg) is negative. Furthermore it is less frequently reported in lymphoma patient when HBV serology shows HBsAg is negative and anti-HBs is positive. We report a case of HBV reactivation following 6 cycle of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for diffuse large B-cell lymphoma in HBsAg negative/anti-HBs positive 58-year-old male, with a review of the literature.

Keyword

Hepatitis B virus; Lymphoma; Rituximab

MeSH Terms

B-Lymphocytes
Doxorubicin
Drug Therapy*
Hepatitis B Surface Antigens
Hepatitis B virus*
Humans
Lymphoma
Lymphoma, B-Cell*
Male
Middle Aged
Vincristine
Rituximab
Doxorubicin
Hepatitis B Surface Antigens
Vincristine
Full Text Links
  • SMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr